295 related articles for article (PubMed ID: 32737030)
21. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
[TBL] [Abstract][Full Text] [Related]
22. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
23. Corded and hyalinized endometrioid endometrial carcinoma with high-grade features: a clinicopathological and TCGA-based molecular analysis.
Travaglino A; Arciuolo D; Santoro A; Raffone A; Pedone Anchora L; Piermattei A; Martinelli M; Mollo A; Onori ME; Minucci A; Inzani F; Fanfani F; Insabato L; Zannoni GF
Virchows Arch; 2023 Apr; 482(4):671-678. PubMed ID: 36550216
[TBL] [Abstract][Full Text] [Related]
24. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
25. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
J Gynecol Oncol; 2023 Sep; 34(5):e85. PubMed ID: 37593813
[TBL] [Abstract][Full Text] [Related]
26. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
Cosgrove CM; Tritchler DL; Cohn DE; Mutch DG; Rush CM; Lankes HA; Creasman WT; Miller DS; Ramirez NC; Geller MA; Powell MA; Backes FJ; Landrum LM; Timmers C; Suarez AA; Zaino RJ; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
Gynecol Oncol; 2018 Jan; 148(1):174-180. PubMed ID: 29132872
[TBL] [Abstract][Full Text] [Related]
27. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
[TBL] [Abstract][Full Text] [Related]
28. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer.
Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S
Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529
[TBL] [Abstract][Full Text] [Related]
30. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.
Sengal AT; Patch AM; Snell CE; Smith DS; Leung SCY; Talhouk A; Williams ED; McAlpine JN; Pollock PM
Clin Cancer Res; 2020 Sep; 26(17):4569-4580. PubMed ID: 32414751
[TBL] [Abstract][Full Text] [Related]
31. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
[TBL] [Abstract][Full Text] [Related]
32. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
[TBL] [Abstract][Full Text] [Related]
33. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups.
Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
[TBL] [Abstract][Full Text] [Related]
34. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas.
Jamieson A; Vermij L; Kramer CJH; Jobsen JJ; Jürgemlienk-Schulz I; Lutgens L; Mens JW; Haverkort MAD; Slot A; Nout RA; Oosting J; Carlson J; Howitt BE; Ip PPC; Lax SF; McCluggage WG; Singh N; McAlpine JN; Creutzberg CL; Horeweg N; Gilks CB; Bosse T
Clin Cancer Res; 2023 Dec; 29(23):4949-4957. PubMed ID: 37773079
[TBL] [Abstract][Full Text] [Related]
35. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
[TBL] [Abstract][Full Text] [Related]
36. Synchronous Endometrial and Ovarian Carcinomas: Pathologic and Molecular Analysis Highlights the Monoclonal Origin of the Lesions.
Guerriero A; Moro M; Angerilli V; Munari G; Santoro L; Alessandrini L; Favero L; Tasca G; Fassan M; Dei Tos AP
Int J Gynecol Pathol; 2024 Jul; 43(4):309-315. PubMed ID: 37922918
[TBL] [Abstract][Full Text] [Related]
37. Premature Classification of Early-stage Endometrioid Ovarian Carcinoma With Mesonephric-like Differentiation as Mesonephric-like Adenocarcinoma.
Miyama Y; Ogasawara A; Hasegawa K; Yasuda M
Int J Gynecol Pathol; 2024 Jul; 43(4):362-372. PubMed ID: 38870078
[TBL] [Abstract][Full Text] [Related]
38. Endometrial Cancer: Transitioning from Histology to Genomics.
Mitric C; Bernardini MQ
Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
[TBL] [Abstract][Full Text] [Related]
39. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.
Hollis RL; Thomson JP; Stanley B; Churchman M; Meynert AM; Rye T; Bartos C; Iida Y; Croy I; Mackean M; Nussey F; Okamoto A; Semple CA; Gourley C; Herrington CS
Nat Commun; 2020 Oct; 11(1):4995. PubMed ID: 33020491
[TBL] [Abstract][Full Text] [Related]
40. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]